Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, multicenter, randomized, open‐label, 2-parallel group, Phase 2 study to evaluate the efficacy and the safety of masitinib at 9 mg/kg/day in combination with docetaxel or with gemcitabine in metastatic Hormone Refractory Prostate Cancer (HRPC) in progression after first line of treatment.

Next Previous
X
Search
Trial Profile

A prospective, multicenter, randomized, open‐label, 2-parallel group, Phase 2 study to evaluate the efficacy and the safety of masitinib at 9 mg/kg/day in combination with docetaxel or with gemcitabine in metastatic Hormone Refractory Prostate Cancer (HRPC) in progression after first line of treatment.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Jun 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Masitinib (Primary) ; Docetaxel; Gemcitabine; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 25 Jun 2015 Status changed from active, no longer recruiting to completed, according to an AB Science media release.
    • 20 Feb 2014 Preliminary results from the masitinib + docetaxel + prednisone arm have been reported in an AB Science media release.
    • 05 Sep 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top